Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Tonato

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
Pain|March 31, 1998
Double-blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer painV Minotti, V De Angelis, E Righetti, et al.
British Journal of Cancer|January 8, 2004
Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancerS Gori, M Colozza, A M Mosconi, et al.
Seminars in Oncology|September 5, 1998
Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trialL Crinò, A M Mosconi, G V Scagliotti, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|April 17, 2007
Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patientsZh Mihaylova, V Ludovini, V Gregorg, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in ItalyS Novello, A Kielhorn, G Stynes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trialL Crinò, A M Mosconi, G Scagliotti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 1996
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II studyU Gatzemeier, F A Shepherd, T Le Chevalier, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 1, 1997
Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in CancerE Ballatori, F Roila, V De Angelis, et al.
Bulletin Du Cancer|March 1, 1997
[A phase II multicenter study of gemcitabine in non small cell lung cancers]T Le Chevalier, M Gottfried, U Gatzemeier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2009
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patientsV Ludovini, G Bellezza, L Pistola, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Pain|March 31, 1998
Double-blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer painV Minotti, V De Angelis, E Righetti, et al.
British Journal of Cancer|January 8, 2004
Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancerS Gori, M Colozza, A M Mosconi, et al.
Seminars in Oncology|September 5, 1998
Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trialL Crinò, A M Mosconi, G V Scagliotti, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|April 17, 2007
Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patientsZh Mihaylova, V Ludovini, V Gregorg, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in ItalyS Novello, A Kielhorn, G Stynes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trialL Crinò, A M Mosconi, G Scagliotti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 1, 1996
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II studyU Gatzemeier, F A Shepherd, T Le Chevalier, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 1, 1997
Clinical and methodological issues in antiemetic therapy: a worldwide survey of experts' opinions. Multinational Association of Supportive Care in CancerE Ballatori, F Roila, V De Angelis, et al.
Bulletin Du Cancer|March 1, 1997
[A phase II multicenter study of gemcitabine in non small cell lung cancers]T Le Chevalier, M Gottfried, U Gatzemeier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2009
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patientsV Ludovini, G Bellezza, L Pistola, et al.
Pageof 12